SCHEMBL7674189

SCHEMBL7674189

CC(C)(C)OC(=O)CNS(=O)(=O)c1ccc(NC(=O)c2ccc(OCc3ccccc3)cc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.58
RAB9A P51151 2/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
ADAMTS4 O75173 2/20 0.55
MMP2 P08253 2/20 0.55
MMP9 P14780 2/20 0.55
MMP14 P50281 2/20 0.55
ADAM17 P78536 2/20 0.55
MMP1 P03956 1/20 0.55
MMP13 P45452 1/20 0.55
ADAMTS5 Q9UNA0 1/20 0.55
MEN1 O00255 5/20 0.53
KMT2A Q03164 5/20 0.53
RXFP1 Q9HBX9 2/20 0.53
LMNA P02545 2/20 0.51
ALDH1A1 P00352 1/20 0.51
MAPT P10636 4/20 0.50
PPARA Q07869 1/20 0.50
KDM4E B2RXH2 1/20 0.49
PRMT1 Q99873 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5892649 0.90 MMP2 (0.67) ADAMTS4MMP2MMP9MMP14ADAM17
SCHEMBL7671694 0.90 KMT2A (0.55) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL7663740 0.88 ALDH1A1 (0.65) SMN1; SMN2MEN1KMT2ALMNAALDH1A1
SCHEMBL7582747 0.88 LMNA (0.65) SMN1; SMN2MMP2MMP9MEN1KMT2A
SCHEMBL7676245 0.87 NPC1 (0.67) NPC1RAB9ASMN1; SMN2ADAMTS4MMP2
SCHEMBL7666345 0.86 LMNA (0.57) SMN1; SMN2MMP1MEN1KMT2ALMNA
SCHEMBL7580808 0.85 HSD17B10 (0.61) NPC1RAB9ASMN1; SMN2MMP2MMP9
SCHEMBL7675460 0.85 SGMS2 (0.58) MEN1KMT2ARXFP1LMNAALDH1A1
SCHEMBL7667880 0.85 LMNA (0.54) SMN1; SMN2MEN1KMT2ALMNAALDH1A1
SCHEMBL7670801 0.83 LMNA (0.52) NPC1RAB9ASMN1; SMN2LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6403644-B1 FOR PREVENTION AND/OR TREATMENT OF DISEASES INDUCED BY OVEREXPRESSION AND EXCESS ACTIVITY OF MATRIX METALLOPROTEINASE; FOR EXAMPLE, RHEUMATOID, ARTHROSTEITIS, UNUSUAL BONE RESORPTION, OSTEOPOROSIS, PERIODONTITIS ONO PHARMACEUTICAL CO., LTD. (JP) 2002-06-11 US disclosed
US-6177466-B1 Sulfonylamino acid derivatives ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-23 US disclosed
EP-0757037-A2 Sulfonylamino acid derivatives as metalloproteinase inhibitors ONO PHARMACEUTICAL CO., LTD. (JP) 1997-02-05 EP disclosed